Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hana Acquires Inex Marqibo; New Development Focus Is Adult & Elderly ALL

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Hana Biosciences initially will develop Marqibo for use in acute lymphoblastic leukemia following acquisition of the sphingosomal vincristine formulation from Inex

You may also be interested in...



Talon’s Marqibo Faces Commercial Challenges After FDA Approval

Talon is preparing to launch the leukemia drug on its own in the first quarter of 2013 but remains in talks with potential strategic partners. The company agreed to monitor whether clinical practices experience safety or technical problems while following the 26-step process for preparing the drug for administration.

Talon May Soon Have First Marqibo Approval In Its Grasp

Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.

Phase II ALL a go for Hana Marqibo

Hana Biosciences has initiated a Phase II Marqibo (vincristine liposomal injection) trial for use in acute lymphoblastic leukemia after acquiring the formulation from Inex (1Pharmaceutical Approvals Monthly April 2006, p. 7). FDA issued a "not approvable" letter to Inex for Marqibo for treatment of relapsed aggressive non-Hodgkin's lymphoma in 2005. The company hopes to initiate a Phase III ALL trial by the end of 2006...

Related Content

Topics

UsernamePublicRestriction

Register

PS003264

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel